Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:305 |
Name | carcinoma |
Definition | A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:6570 DOID:2428 |
Path | disease disease of cellular proliferation cancer cell type cancer carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT01148849 | Phase I | Margetuximab-cmkb | Safety Study of MGAH22 in HER2-positive Carcinomas | Completed | USA | 1 |
NCT01427322 | Phase I | Lapatinib | Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease | Terminated | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT02637531 | Phase I | Pembrolizumab Eganelisib | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Unknown status | USA | 0 |
NCT02648490 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | Completed | USA | 1 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT03094169 | Phase I | AVID100 | AVID100 in Advanced Epithelial Carcinomas | Terminated | USA | 0 |
NCT03391973 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) | Active, not recruiting | CAN | 0 |
NCT03396471 | Phase II | Pembrolizumab | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | Terminated | USA | 0 |
NCT03436563 | Phase Ib/II | Bintrafusp alfa | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Active, not recruiting | USA | 0 |
NCT03570619 | Phase II | Ipilimumab + Nivolumab | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) | Completed | USA | 0 |
NCT03852511 | Phase I | NG-350A | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) | Completed | USA | 0 |
NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
NCT04053283 | Phase I | NG-641 | First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector | Active, not recruiting | USA | 0 |
NCT04131621 | Phase II | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) | Unknown status | DEU | 0 |
NCT04147819 | Phase I | BAY2701439 | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Completed | USA | GBR | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04520711 | Phase I | CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells | Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers | Active, not recruiting | USA | 0 |
NCT04648826 | Phase Ib/II | Azacitidine + Bintrafusp alfa | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | Withdrawn | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05165433 | Phase I | NG-350A + Pembrolizumab | Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY) | Active, not recruiting | USA | GBR | 0 |
NCT05239143 | Phase I | P-MUC1C-ALLO1 CAR-T cells + Rimiducid | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05349890 | Phase I | CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | Enrolling by invitation | USA | 0 |
NCT05639972 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Not yet recruiting | USA | 0 |
NCT05976828 | Phase I | IBRX-042 | IBRX-042 In Subjects With HPV-Associated Tumors | Recruiting | USA | 0 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |
NCT06092580 | Phase I | AWT020 | Phase 1 Study of AWT020 in Advanced Cancer | Recruiting | AUS | 0 |
NCT06152523 | Phase II | MEDI5752 + Monalizumab | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI) | Not yet recruiting | FRA | 0 |
NCT06290388 | Phase Ib/II | 23ME-01473 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT06576037 | Phase I | CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Not yet recruiting | USA | 0 |